The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study
Open accessAbstract
We have studied focal changes in dopaminergic function throughout the brain volume in early and advanced Parkinson's disease by applying statistical parametric mapping (SPM) to 3D [(18)F]dopa-PET. Data from seven early hemi-Parkinson's disease and seven advanced bilateral Parkinson's disease patients were compared with that from 12 normal controls. Parametric images of [(18)F]dopa influx rate constant (K(i)(o)) were generated for each subject from dynamic 3D [(18)F]dopa datasets and transformed into standard stereotactic space. Significant changes in mean voxel [(18)F]dopa K(i)(o) values between the normal control group and each Parkinson's disease group were localized with SPM. Conventional region of interest analysis was also applied to comparable regions on the untransformed image datasets. In early left hemi-Parkinson's disease, significant extrastriatal increases in [(18)F]dopa K(i)(o) were observed in the left anterior cingulate gyrus and the dorsal midbrain region (P < 0.05, corrected) along with decreases in striatal [(18)F]dopa K(i)(o). In advanced Parkinson's disease, significant extrastriatal decreases in [(18)F]dopa K(i)(o) were observed in the ventral and dorsal midbrain regions (P < 0.05, corrected). No significant changes in [(18)F]dopa K(i)(o) were observed in the anterior cingulate region. In a direct comparison between the early and late Parkinson's disease groups, we observed relative [(18)F]dopa K(i)(o) reductions in ventral and dorsal midbrain, and dorsal pontine regions along with striatal [(18)F]dopa K(i)(o) reductions. Similiar results were found with a region of interest approach, on non-transformed data, except for the focal midbrain [(18)F]dopa K(i)(o) increase seen in early Parkinson's disease. In conclusion, using SPM with [(18)F]dopa-PET, we have objectively localized changes in extrastriatal, pre-synaptic dopaminergic function in Parkinson's disease. The significance of the increased dopaminergic activity of anterior cingulate in early Parkinson's disease remains unclear, but may be compensatory. The [(18)F]dopa signal in dorsal midbrain and pontine regions suggests that [(18)F]dopa is taken up by serotonergic and noradrenergic neurons which also degenerate in advanced Parkinson's disease. This suggests, therefore, that Parkinson's disease is a monoaminergic neurodegenerative disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Self-citationHandbook of Chemical Neuroanatomy
Stern, C. D. (1986) · Neurochemistry International · doi:10.1016/0197-0186(86)90021-5 · Cited by 4,151
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Research works printed but not linked: 10
- Badawi RD. 3D-Mode acquisition in clinical PET [editorial]. Nuc Med Commun1997; 18: 801–4. · doi:10.1097/00006231-199704000-00079
- Bailey DL. 3D acquisition and reconstruction in positron emission tomography. [Review]. Ann Nucl Med1992; 6: 123–30. · doi:10.1007/bf03178303
- Cherry SR, Meikle SR, Hoffman EJ. Correction and characterization of scattered events in three-dimensional PET using scanners with retractable septa. J Nucl Med1993; 34: 671–8.
- Cumming P, Gjedde A, Reith J. Controversies arising from recent FDOPA articles [letter; comment] [see comments]. J Nucl Med1997; 38: 1267–71. Comment on: J Nucl Med 1996; 37: 209–22, Comment on: J Nucl Med 1996; 37: 432–7, Comment in: J Nucl Med 1997; 38: 1267–71.
- Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhet A, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease [see comments]. J Nucl Med1996; 37: 209–16. Comment in: J Nucl Med 1997; 38: 1267–71.
- Ichise M, Ballinger JR. Physiologic modelling of PET data: quantitative conflict and challenge [editorial; comment]. J Nucl Med1997; 38: 1266–72. Comment on: J Nucl Med 1997; 38: 1267–2.
- Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in parkinson's disease: studies in an animal model. Is J Med Sci1982; 18: 159–62.
- Richardson MP, Koepp MJ, Brooks DJ, Fish DR, Duncan JS. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an 11C-flumazenil PET study. Ann Neurol1996; 40: 188–98. · DOI
- Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett1991; 127: 203–6. · doi:10.1016/0304-3940(91)90794-t
- Trebossen R, Bendriem B, Fontaine A, Frouin V, Remy P. Quantification of the [18F]fluorodopa uptake in the human striata in 3D PET with the ETM scatter correction. In: Myers R, Cunningham V, Bailey DL, Jones T, editors. Quantification of brain function using PET. San Diego: Academic Press; 1996. p. 88–92. · doi:10.1016/b978-012389760-2/50020-7
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
Cools, R., & D'Esposito, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.028 · Cited by 1,673
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Self-citationIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Self-citationRemy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,040
Self-citationThe distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 965
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
Rodriguez-Oroz, M. C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., & Obeso, J. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70293-5 · Cited by 863
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationLee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 573
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Capuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
“Indeed, in early-stage PD, increased (18)F-dopa uptake has been reported in the frontal cortex, ostensibly reflecting compensation for neuronal loss in the basal ganglia.(39,41) Also, in contrast to PD, interferon alfa administration was associated with decreased dopamine turnover.”
ResultDopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [ 18 F]-DOPA PET Imaging Study
Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., Murray, R. M., & McGuire, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010160 · Cited by 343
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction
Pavese, N., Metta, V., Bose, S. K., Chaudhuri, K. R., & Brooks, D. J. (2010) · Brain · doi:10.1093/brain/awq268 · Cited by 333
Self-citationKuo, Y.-M., Li, Z., Jiao, Y., Gaborit, N., Pani, A. K., Orrison, B. M., Bruneau, B. G., Giasson, B. I., Smeyne, R. J., Gershon, M. D., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq038 · Cited by 286
Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function
Cropley, V. L., Fujita, M., Innis, R. B., & Nathan, P. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.004 · Cited by 283
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease
Sawamoto, N., Piccini, P., Hotton, G., Pavese, N., Thielemans, K., & Brooks, D. J. (2008) · Brain · doi:10.1093/brain/awn054 · Cited by 263
Self-citationThe role of the striatum and hippocampus in planning: A PET activation study in Parkinson's disease
Dagher, A. (2001) · Brain · doi:10.1093/brain/124.5.1020 · Cited by 259
Self-citationThe heterogeneity of idiopathic Parkinson's disease
Foltynie, T., Brayne, C., & Barker, R. A. (2002) · Journal of Neurology · doi:10.1007/pl00007856 · Cited by 255
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease
Piccini, P., Pavese, N., Hagell, P., Reimer, J., Björklund, A., Oertel, W. H., Quinn, N. P., Brooks, D. J., & Lindvall, O. (2005) · Brain · doi:10.1093/brain/awh649 · Cited by 254
Self-citationDeserno, L., Huys, Q. J. M., Boehme, R., Buchert, R., Heinze, H.-J., Grace, A. A., Dolan, R. J., Heinz, A., & Schlagenhauf, F. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417219112 · Cited by 233
Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
Robbins, T. W., & Cools, R. (2014) · Movement Disorders · doi:10.1002/mds.25853 · Cited by 235
Vallesi, A., Shallice, T., & Walsh, V. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhj163 · Cited by 218
Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620060-00004 · Cited by 147
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
“In agreement with previous studies (Rakshi et al., 1999; Whone et al., 2003a; Moore et al., 2008), baseline mean 18 F-dopa uptake in globus pallidus interna and midbrain raphe was significantly raised in our early PD patients.”
ResultSelf-citationIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Self-citationMembers, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Live assessment of DA neuron content in patients with PD indicates a causal correlation between nigrostriatal DA content and the severity of PD motor deficits (Benamer et al. 2000; Lin et al. 2014; Pirker 2003; Rakshi et al. 1999; Rinne et al. 1995; Tissingh et al. 1998).”
BackgroundLudolph, A. G., Kassubek, J., Schmeck, K., Glaser, C., Wunderlich, A., Buck, A. K., Reske, S. N., Fegert, J. M., & Mottaghy, F. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.025 · Cited by 83
“Since there is only few anatomical information in the parametric images of the Ki values a sum image of the 25 frames of the dynamic FDOPA study was used for coregistration and the parameters were than applied to the parametric Ki image (Rakshi et al., 1999).”
Heng, N., Malek, N., Lawton, M. A., Nodehi, A., Pitz, V., Grosset, K. A., Ben‐Shlomo, Y., & Grosset, D. G. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13687 · Cited by 64
5.4 Dopaminergic Modulation of Flexible Cognitive Control in Humans
Cools, R., & D’Esposito, M. (2009) · Dopamine Handbook · doi:10.1093/acprof:oso/9780195373035.003.0017 · Cited by 46
Increased presynaptic dopamine function in Asperger syndrome
Nieminen-von Wendt, T. S., Metsähonkala, L., Kulomäki, T. A., Aalto, S., Autti, T. H., Vanhala, R., Eskola, O., Bergman, J., Hietala, J. A., & von Wendt, L. O. (2004) · NeuroReport · doi:10.1097/00001756-200404090-00003 · Cited by 40
Wolpe, N., Nombela, C., & Rowe, J. B. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01514 · Cited by 18
Berrío Sánchez, J., Cucarian Hurtado, J., Barcos Nunes, R., & de Oliveira, A. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0011 · Cited by 7
Metadata
- Authors
- Rakshi, J. S., Uema, T., Ito, K., Bailey, D. L., Morrish, P. K., Ashburner, J., Dagher, A., Jenkins, I. H., Friston, K. J., & Brooks, D. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-09
- Volume
- 122
- Issue
- 9
- Pages
- 1637-1650
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2154272661
- Cited by
- 270
- References
- 55
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.